On the Discovery of TOR As the Target of Rapamycin.
Identifieur interne : 000C52 ( Main/Exploration ); précédent : 000C51; suivant : 000C53On the Discovery of TOR As the Target of Rapamycin.
Auteurs : Joseph Heitman [États-Unis]Source :
- PLoS pathogens [ 1553-7374 ] ; 2015.
Descripteurs français
- KwdFr :
- MESH :
- effets des médicaments et des substances chimiques : Sérine-thréonine kinases TOR.
- usage thérapeutique : Antibactériens, Immunosuppresseurs, Sirolimus.
- Animaux, Humains, Transplants.
English descriptors
- KwdEn :
- MESH :
- chemical , drug effects : TOR Serine-Threonine Kinases.
- chemical , therapeutic use : Anti-Bacterial Agents, Immunosuppressive Agents, Sirolimus.
- Animals, Humans, Transplants.
DOI: 10.1371/journal.ppat.1005245
PubMed: 26540102
PubMed Central: PMC4634758
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">On the Discovery of TOR As the Target of Rapamycin.</title><author><name sortKey="Heitman, Joseph" sort="Heitman, Joseph" uniqKey="Heitman J" first="Joseph" last="Heitman">Joseph Heitman</name><affiliation wicri:level="2"><nlm:affiliation>Departments of Molecular Genetics and Microbiology (MGM), Pharmacology and Cancer Biology, and Medicine, Duke University Medical Center, Durham, North Carolina, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Molecular Genetics and Microbiology (MGM), Pharmacology and Cancer Biology, and Medicine, Duke University Medical Center, Durham, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation><affiliation wicri:level="2"><nlm:affiliation>Tri-Institutional (Duke, UNC, NC State) Molecular Mycology and Pathogenesis Training Program (Tri-I MMPTP), Duke University Medical Center, Durham, North Carolina, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Tri-Institutional (Duke, UNC, NC State) Molecular Mycology and Pathogenesis Training Program (Tri-I MMPTP), Duke University Medical Center, Durham, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26540102</idno><idno type="pmid">26540102</idno><idno type="doi">10.1371/journal.ppat.1005245</idno><idno type="pmc">PMC4634758</idno><idno type="wicri:Area/Main/Corpus">000B54</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000B54</idno><idno type="wicri:Area/Main/Curation">000B54</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000B54</idno><idno type="wicri:Area/Main/Exploration">000B54</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">On the Discovery of TOR As the Target of Rapamycin.</title><author><name sortKey="Heitman, Joseph" sort="Heitman, Joseph" uniqKey="Heitman J" first="Joseph" last="Heitman">Joseph Heitman</name><affiliation wicri:level="2"><nlm:affiliation>Departments of Molecular Genetics and Microbiology (MGM), Pharmacology and Cancer Biology, and Medicine, Duke University Medical Center, Durham, North Carolina, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Molecular Genetics and Microbiology (MGM), Pharmacology and Cancer Biology, and Medicine, Duke University Medical Center, Durham, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation><affiliation wicri:level="2"><nlm:affiliation>Tri-Institutional (Duke, UNC, NC State) Molecular Mycology and Pathogenesis Training Program (Tri-I MMPTP), Duke University Medical Center, Durham, North Carolina, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Tri-Institutional (Duke, UNC, NC State) Molecular Mycology and Pathogenesis Training Program (Tri-I MMPTP), Duke University Medical Center, Durham, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author></analytic><series><title level="j">PLoS pathogens</title><idno type="eISSN">1553-7374</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals (MeSH)</term><term>Anti-Bacterial Agents (therapeutic use)</term><term>Humans (MeSH)</term><term>Immunosuppressive Agents (therapeutic use)</term><term>Sirolimus (therapeutic use)</term><term>TOR Serine-Threonine Kinases (drug effects)</term><term>Transplants (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux (MeSH)</term><term>Antibactériens (usage thérapeutique)</term><term>Humains (MeSH)</term><term>Immunosuppresseurs (usage thérapeutique)</term><term>Sirolimus (usage thérapeutique)</term><term>Sérine-thréonine kinases TOR (effets des médicaments et des substances chimiques)</term><term>Transplants (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>TOR Serine-Threonine Kinases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Bacterial Agents</term><term>Immunosuppressive Agents</term><term>Sirolimus</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Sérine-thréonine kinases TOR</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antibactériens</term><term>Immunosuppresseurs</term><term>Sirolimus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term><term>Transplants</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Humains</term><term>Transplants</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26540102</PMID><DateCompleted><Year>2016</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1553-7374</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>11</Issue><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>PLoS pathogens</Title><ISOAbbreviation>PLoS Pathog</ISOAbbreviation></Journal><ArticleTitle>On the Discovery of TOR As the Target of Rapamycin.</ArticleTitle><Pagination><MedlinePgn>e1005245</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.ppat.1005245</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Heitman</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departments of Molecular Genetics and Microbiology (MGM), Pharmacology and Cancer Biology, and Medicine, Duke University Medical Center, Durham, North Carolina, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tri-Institutional (Duke, UNC, NC State) Molecular Mycology and Pathogenesis Training Program (Tri-I MMPTP), Duke University Medical Center, Durham, North Carolina, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>11</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Pathog</MedlineTA><NlmUniqueID>101238921</NlmUniqueID><ISSNLinking>1553-7366</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber><NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>W36ZG6FT64</RegistryNumber><NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019737" MajorTopicYN="Y">Transplants</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26540102</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.1005245</ArticleId><ArticleId IdType="pii">PPATHOGENS-D-15-02348</ArticleId><ArticleId IdType="pmc">PMC4634758</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Caroline du Nord</li></region></list><tree><country name="États-Unis"><region name="Caroline du Nord"><name sortKey="Heitman, Joseph" sort="Heitman, Joseph" uniqKey="Heitman J" first="Joseph" last="Heitman">Joseph Heitman</name></region><name sortKey="Heitman, Joseph" sort="Heitman, Joseph" uniqKey="Heitman J" first="Joseph" last="Heitman">Joseph Heitman</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C52 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000C52 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= RapamycinFungusV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26540102
|texte= On the Discovery of TOR As the Target of Rapamycin.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26540102" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a RapamycinFungusV1
| This area was generated with Dilib version V0.6.38. |  |